Dr. Geeta Shroff's Stem Cell Technology
About Dr. Geeta Shroff and her technology
Dr. Geeta Shroff is an infertility expert located in Delhi, India, and the first individual in the world to develop an infinite number of pure human embryonic stem cell lines from using just one donated embryo. The single donated embryo originated from an IVF donor, which negates the debate over destroying numerous embryos for therapy.
Her partnering physician and anesthesiologist is Dr. Ashish Verma. The two have been working together since before the discovery of this technology in 1999. They have recently filed a patent with the World Intellectual Property Organization, covering over 126 countries including India and the United States.
Every day we hear of treatments around the world using stem cells (fetal, umbilical cord, adult, nasal, rats, etc.). Dr. Geeta Shroff has developed the only purely human embryonic stem cell lines that do not show any immune reaction in the body. Embryonic stem cells do not have any antigenic proteins on their surface and therefore do not require immunosuppressant drugs to combat rejection.
Importantly, despite the theoretical risks of human embryonic stem cells, no side effects have been reported from her therapy. Dr. Geeta Shroff practices under the guise of the Indian Health Council, which allows her to conduct clinical trials on incurable or terminal patients. She operates out of two hospitals in Delhi, India, which have ISO certifications (International Organization for Standardization) and BCI certifications (awarded by a British independent agency). Her lab is in compliance with Good Manufacturing Practice and Good Labratory Practice.
Scientific explanation of this technology
The following text was extracted from an article by Dr. Laurance Johnston Ph.D. "Embryonic Stem Cell Therapy" was published on the Healing Therapies website.
Basically, after an egg is fertilized, an embryo is formed, which then splits into a two cells. In Stem Cell Now (2006), author Christopher Scott compares the process to dividing a soap bubble with a knife, creating two smaller bubbles within the confines of the original. Cut again, and it becomes four bubbles or a four-cell embryo. This division goes on, successively creating 8, 16, 32, 64, 128-cell embryo, the total volume changing little.
Between four and six days, the cells rearrange into two layers: an outer layer that will develop into placental and amniotic tissue and a few dozen cells called the inner-cell mass (ICM) which turns into everything else. Now labeled a blastocyst, the embryo is about 0.1-mm across or the size of the period at the end of this sentence.
As the cells continue to develop, they increasingly lose their omnipotent nature. After about two weeks, the ICM starts to organize into three specific layers that become our various tissues: 1) ectodermal layer (developing into nerve, skin, etc), 2) mesodermal (turning into blood, muscle, bone, etc), and 3) endodermal (differentiating into the gut, liver, pancreas, bladder, etc.).
To obtain ESCs, the ICM cells are isolated before they start turning into these layers, and grown in culture. The culturing technology has only recently emerged and requires sophisticated methodology and skill. For example, scientists have had to grow the cells on a layer of animal cells to provide nutrients and the signals needed to keep the cells from further differentiating.
In this regard, Shroff’s breakthrough is that she has grown ESCs without using any animal products, including these feeder cells. By keeping the cells purely “human” in nature, she makes them more amenable to transplantation. The cells from her “mother culture” are further adapted or primed to create daughter cultures targeting specific disorders. Hence, a more specialized cell line will be used to treat individuals with SCI, stroke, diabetes, etc.
According to Dr. Shroff, the transplanted cells will home into the tissue where they are needed, to begin regeneration. Thus, even when introduced by more remote intravenous or intramuscular routes, the cells' physiological affinity for the target tissue will cause them to migrate where they are needed.
It can be said that the complete effect of human embryonic stem cells transplanted into a patient closely resembles the time frame of the human embryo’s development. This includes nine months of gestation, and then the growth of a newborn baby after delivery up until five years of age where the nervous system reaches its full potential. Although often response in patients is seen immediately after transplantation, the embryonic stem cells continue their developmental process as per their pre-programmed time frame.
This human embryonic stem cell treatment has been used in a number of conditions in clinical trials on patients from all over the world at Dr. Geeta Shroff’s clinics. All have shown improvement of some kind. Some of these conditions include Diabetes, spinal cord injury, Parkinson’s, Multiple Sclerosis, ALS, Chronic Lyme Disease, cerebral palsy, autism, etc. Patients with complete spinal injuries as old as 16 years are seeing dramatic results such as regaining bowel and bladder control and function in their legs; Diabetics are weaning off their insulin or have been able to withdraw from medication completely; and neurodegenerative disease patients with brain lesions are seeing reversals.
*Some of this information has been used with permission from Amanda Boxtel's blog, Awakenings.
To read more....
Here's a Global Post Article on Dr. Shroff and Amy's treatment.
For related information, please read Stem Cell Cheat Sheet.
For an interview with Dr. Ashish from the clinic, read Stem Cell Curiosity: Answers From India.
Amy answers frequently asked questions about her India treatment.